JAK2 and myeloproliferative neoplasm: Excitingly, however, Jayavelu et al. [64] demonstrated that the combination of JAK2 and MEK inhibitor treatment induced reductions in JAK2-V617F allele burden in a xenograft model of primary MPN patient cells, and these results included evidence of molecular eradication of and selectivity for JAK2-V617F cells.